Previous Close | 0.0000 |
Open | 0.1181 |
Bid | 0.0295 x 0 |
Ask | 0.0342 x 0 |
Day's Range | 0.1181 - 0.1181 |
52 Week Range | 0.0343 - 0.2540 |
Volume | |
Avg. Volume | 12 |
Market Cap | 4.627M |
Beta (5Y Monthly) | 1.60 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2600 |
Earnings Date | Jan 27, 2025 - Jan 31, 2025 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Valeo Pharma Inc. (TSX: VPH) (FSE: VP2), a Canadian pharmaceutical company, announced today that the Québec Superior Court (Commercial Division) (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries VPI Pharmaceuticals Inc. / VPI Pharmaceutiques Inc. and Valeo Pharma Corp. (collectively, the "Company" or "Valeo") protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA").
Valeo Pharma Inc. (TSX: VPH) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the third quarter ended July 31, 2024.